» Articles » PMID: 9058709

Human Platelets Display High-affinity Receptors for Thrombopoietin

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1997 Mar 15
PMID 9058709
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Thrombopoietin (Tpo) is a major regulator of megakaryopoiesis both in vivo and in vitro. Tpo initiates its biologic effects by binding to the Mpl receptor, which is a member of the hematopoietin receptor family. To define the Tpo binding characteristics of the Mpl receptor, we iodinated purified 70-kD recombinant human Tpo using the Bolton-Hunter reagent. Autoradiographic analysis of (125)I-Tpo binding to normal human marrow mononuclear cells showed many grains specifically associated with megakaryocytes; there were no grains specifically associated with myeloblasts or erythroblasts. Equilibrium binding experiments with (125)I-Tpo and normal human platelets showed a single class of high-affinity receptors (kd, 190 pmol/L) with approximately 30 Mpl receptors per platelet. Affinity cross-linking with (125)I-Tpo showed that the Mpl receptor on platelets is of molecular weight approximately 98 kD. Despite their sequence similarity, erythropoietin and Tpo did not cross-compete for binding to BaF3 cells engineered to coexpress Mpl receptor and erythropoietin receptor. Progeny of normal human burst-forming units-erythroid (BFU-E) contained Mpl receptor mRNA, and flow cytometric analysis showed the presence of Mpl receptor protein on the surface of these cells. These data indicate that display of the Mpl receptor is not limited to the megakaryocytic lineage, but also includes progeny of BFU-E. Like receptors for other hematopoietic cytokines, the binding affinity of the Mpl receptor for Tpo is high, with relatively few receptors displayed per cell. These results suggest that the effects of Tpo to speed red blood cell recovery after myelosuppressive therapy in vivo and to enhance colony-forming unit-erythroid generation in vitro may be mediated by direct interaction of Tpo and erythroid progenitor cells.

Citing Articles

Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.

Zheng S, Perdomo J Curr Issues Mol Biol. 2024; 46(11):11942-11956.

PMID: 39590303 PMC: 11592706. DOI: 10.3390/cimb46110709.


Investigating the Role of Anti-TPO Antibodies in HIV-Associated Thrombocytopenia before and after Initiation of HAART: A Case-Control Longitudinal Study.

Tsiakalos A, Routsias J, Schinas G, Georgiadou S, Sipsas N, Akinosoglou K Viruses. 2023; 15(11).

PMID: 38005902 PMC: 10675467. DOI: 10.3390/v15112226.


Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection.

Ichimata S, Kobayashi M, Honda K, Shibata S, Matsumoto A, Kanno H World J Gastroenterol. 2017; 23(35):6540-6545.

PMID: 29085203 PMC: 5643279. DOI: 10.3748/wjg.v23.i35.6540.


Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia.

Park S, Yoon S, Lee J, Park J, Jang J, Lee J Int J Hematol. 2015; 103(1):44-52.

PMID: 26511480 DOI: 10.1007/s12185-015-1889-7.


Circulating thrombopoietin levels in normal healthy blood donors and in aplastic anemia patients in relation to disease severity.

Singh A, Verma A, Nityanand S, Chaudhary R, Elhence P Asian J Transfus Sci. 2015; 9(1):70-3.

PMID: 25722577 PMC: 4339937. DOI: 10.4103/0973-6247.150956.